ELDN
Eledon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.02
+3.07%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
Market Cap
$245.41M
MomentumView details →
1D Return
+3.07%
YTD Return
+101.04%
RSI (14)
34.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
Market Cap
$245.41M
RSI (14)
34.3
MomentumView details →
1D Return
+3.07%
YTD Return
+101.04%
SummaryUpdated Jun 1, 2026
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Irvine, California. Originally known as Novus Therapeutics, Inc., the company underwent a strategic transformation and changed its name to Eledon Pharmaceuticals in January 2021. The company focuses on developing innovative medicines for patients living with autoimmune diseases, amyotrophic lateral sclerosis (ALS), and those requiring organ or cell-based transplants.
Similar companies
Latest newsMore news →
Eledon Pharmaceuticals dosed the first patients under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant.1d agoEledon Pharmaceuticals enrolled the first patients in a new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant.1d agoEledon Pharmaceuticals submitted an Investigational New Drug application to the U.S. FDA for a registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes.1d ago